Abstract
The translation of promising preclinical treatments into effective drugs for Alzheimer's disease (AD) has been challenging. One of the most potent risk factors for sporadic AD is carrier status of the epsilon 4 allele of the apolipoprotein E gene (E4). E4 carriers show a differential response to several therapies which are being investigated as AD treatments, including acetylcholinesterase inhibitors and therapeutics with vascular and metabolic targets. The differential treatment responses of E4 carriers may partially explain why some treatments show a null effect in clinical trials. Understanding the reasons behind these responses is not only important for clinical practice, but may also help us elucidate mechanisms for this neurodegenerative disease.
Keywords: Alzheimer's disease, treatments, APOE genotype.
Current Pharmaceutical Design
Title:The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Volume: 21 Issue: 1
Author(s): Angela J. Hanson, Suzanne Craft and William A. Banks
Affiliation:
Keywords: Alzheimer's disease, treatments, APOE genotype.
Abstract: The translation of promising preclinical treatments into effective drugs for Alzheimer's disease (AD) has been challenging. One of the most potent risk factors for sporadic AD is carrier status of the epsilon 4 allele of the apolipoprotein E gene (E4). E4 carriers show a differential response to several therapies which are being investigated as AD treatments, including acetylcholinesterase inhibitors and therapeutics with vascular and metabolic targets. The differential treatment responses of E4 carriers may partially explain why some treatments show a null effect in clinical trials. Understanding the reasons behind these responses is not only important for clinical practice, but may also help us elucidate mechanisms for this neurodegenerative disease.
Export Options
About this article
Cite this article as:
Hanson Angela J., Craft Suzanne and Banks A. William, The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease, Current Pharmaceutical Design 2015; 21 (1) . https://dx.doi.org/10.2174/1381612820666141020164222
DOI https://dx.doi.org/10.2174/1381612820666141020164222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Current Alzheimer Research Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders
Current Alzheimer Research The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Current State of Development of Genome Analysis in Livestock
Current Genomics Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors
Current Pharmaceutical Design Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Skin Lipid Synthesis Inhibition: A Possible Means for Enhancing Percutaneous Delivery of Levodopa
Current Drug Delivery Pharmacomimetics of Exercise: Novel Approaches for Hippocampally- Targeted Neuroprotective Agents
Current Medicinal Chemistry The Application of Proteomics in Neurology
Current Proteomics Inhibition of Protein Misfolding and Aggregation by Small Rationally-Designed Peptides
Current Pharmaceutical Design AβPP-induced UPR Transcriptomic Signature of Glial Cells to Oxidative Stress as an Adaptive Mechanism to Preserve Cell Function and Survival
Current Alzheimer Research Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Current Alzheimer Research In vitro Antioxidant and Acetylcholinesterase Inhibitory Activities of Fractions from Centella asiatica (Linn.) Extract
Current Bioactive Compounds Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets Patterns of Gray and White Matter Changes in Individuals at Risk for Alzheimer’s Disease
Current Alzheimer Research Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Propofol Inhibits Caspase-3 in Astroglial Cells: Role of Heme Oxygenase-1
Current Neurovascular Research Can a Direct IADL Measure Detect Deficits in Persons with MCI?
Current Alzheimer Research